Published online Feb 27, 2023. doi: 10.4240/wjgs.v15.i2.303
Peer-review started: November 19, 2022
First decision: January 3, 2023
Revised: January 16, 2023
Accepted: February 9, 2023
Article in press: February 9, 2023
Published online: February 27, 2023
Processing time: 99 Days and 22.8 Hours
Clostridioides difficile infection (CDI) is a global health problem. The association of appendectomy on the severity and prognosis of CDI has been reported in many literatures, but there are still contradictions. In a retrospective study entitled “Patients with Closterium diffuse infection and prior appendectomy may be prone to word outcomes” published in World J Gastrointest Surg 2021, the author found that prior appendectomy affects the severity of CDI. Appendectomy may be a risk factor for increasing the severity of CDI. Therefore, it is necessary to seek alternative treatment for patients with prior appendectomy when they are more likely to have severe or fulminant CDI.
Core Tip: The fecal microbiota transplantation (FMT) is a universally approved treatment plan for recurrent Clostridioides difficile infection (CDI). We believe that early FMT is a better choice for patients with CDI and prior appendectomy even if they are not diagnosed as recurrent CDI. FMT can change the composition of patients' intestinal microbiota in a lasting way to prevent worse outcomes.
- Citation: Zhao JW, Chang B, Sang LX. Fecal microbiota transplantation as potential first-line treatment for patients with Clostridioides difficile infection and prior appendectomy. World J Gastrointest Surg 2023; 15(2): 303-306
- URL: https://www.wjgnet.com/1948-9366/full/v15/i2/303.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v15.i2.303
We read with great interest the article by Shaikh et al[1] entitled patients with “Clostridium difficile infection and prior appendectomy may be prone to worse outcomes”. They studied the association of appendectomy on the severity and prognosis of Clostridioides difficile infection (CDI). CDI remains a major health care problem globally. Due to super virulent strains and the abuse of antibiotics, the incidence and severity of CDI have been increasing since 2000[2].
We found that there were contradictions in the discussion of the role of prior appendectomy on CDI in the previous literature. The sample size of this article is much larger than that of previous studies, which is one of its strengths, thus providing more powerful evidence for future research on the relationship between prior appendectomy and CDI. This study did not prove that the risk of CDI recurrence in patients with prior appendectomy was increased. However, appendectomy affected the severity of CDI and was also related to toxic megacolon and colectomy, which was consistent with the conclusion of Yong et al[3], who stated that appendectomy may be a risk factor for the increase in CDI severity. The specific reason still needs to be determined via experimental and clinical research. It is speculated that the appendix is the "safe house" of normal colon bacteria[4], and appendectomy may reduce intestinal immune reactivity, which may reduce intestinal resistance to Clostridioides difficile and lead to a worse outcome of CDI. To further confirm and validate the results of this paper, a larger prospective study is needed.
It is necessary to seek a new treatment plan when patients with prior appendectomy are more likely to have severe or fulminant CDI. The fecal microbiota transplantation (FMT) is a method approved by most international guidelines for recurrent CDI[5,6]. Although FMT has been proven to be safe and effective in recurrent infections, its efficacy in severe or fulminant CDI is still unclear. A series of studies show that FMT combined with antibiotics can reduce the mortality of severe and fulminant CDI[7] and reduces the occurrence of surgery[8]. Early FMT can improve the survival rate of patients with severe CDI. Severe CDI patients without FMT have a serious prognosis and a very high mortality rate (30%-60%)[9]. FMT treatment in primary severe CDI has a very low disease recurrence rate[10]. Tixier et al[11] provided low-quality evidence to support FMT as a safe and effective treatment for adult severe and fulminant CDI. At present, some scholars believe that FMT can be used as the first-line treatment for severe and fulminant CDI[12], but more evidence is needed.
FMT should be performed by an experienced team after a thorough risk assessment. In clinical practice, the need for FMT or even multiple FMTs can be assessed by establishing a risk assessment system that includes prior appendectomy as a risk factor. Additionally, it has been demonstrated that the presence of pseudomembranous lesions under colonoscopy and highly pathogenic CDI strains are predictors of FMT failure, so patients with severe or fulminant CDI may require multiple FMTs until the pseudomembranous lesions disappear and clinical remission is achieved[13]. We believe that early FMT is a better option to modify the composition of the patient's gut microbiota in a durable way, prophylactically reducing the incidence of toxic megacolon as well as colectomy.
Many risk factors for CDI are immutable (such as advanced age)[14]. The current prevention strategies mainly focus on improving hand hygiene, contact isolation, environmental purification and antibiotic management plans[15]. These strategies have been proven to be effective but still have limitations. Shaikh made us realize that new strategies are needed to prevent CDI when dealing with specific patients. Although probiotics are not included in the guidelines for the prevention and treatment of CDI, some probiotic such as strains from Saccharomyces, Bifidobacterium, or Lactobacillus genera have potential protective effect against Clostridioides difficile[16]. For patients who have undergone prior appendectomy, preventive improvement of intestinal flora is the key to avoid worse outcomes.
Many studies have confirmed the long-term safety of FMT for recurrent CDI[17]. A multicenter long-term follow-up study also showed that FMT is successful and safe for patients with severe or refractory CDI[18]. These findings all emphasize the value of FMT in avoiding the repeated use of antibiotics which may cause dysbiosis of the intestinal microbial community permanently. FMT can restore the biological diversity of intestinal microbiota to restore the normal intestinal function. All these enlighten us that FMT has the potential to be the first-line treatment for patients with CDI and prior appendectomy.
Provenance and peer review: Unsolicited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Gastroenterology and hepatology
Country/Territory of origin: China
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C, C
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Bharara T, India; Lee JG, South Korea; Link A, Germany S-Editor: Zhang H L-Editor: A P-Editor: Zhang H
1. | Shaikh DH, Patel H, Munshi R, Sun H, Mehershahi S, Baiomi A, Alemam A, Pirzada U, Nawaz I, Naher K, Hanumanthu S, Nayudu S. Patients with Clostridium difficile infection and prior appendectomy may be prone to worse outcomes. World J Gastrointest Surg. 2021;13:1436-1447. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
2. | Surawicz CM, Alexander J. Treatment of refractory and recurrent Clostridium difficile infection. Nat Rev Gastroenterol Hepatol. 2011;8:330-339. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 5.3] [Reference Citation Analysis (0)] |
3. | Yong FA, Alvarado AM, Wang H, Tsai J, Estes NC. Appendectomy: a risk factor for colectomy in patients with Clostridium difficile. Am J Surg. 2015;209:532-535. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
4. | Sanders NL, Bollinger RR, Lee R, Thomas S, Parker W. Appendectomy and Clostridium difficile colitis: relationships revealed by clinical observations and immunology. World J Gastroenterol. 2013;19:5607-5614. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis (0)] |
5. | van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Norén T, Allerberger F, Coia JE, Goorhuis A, van Rossen TM, Ooijevaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild MJGT, Fitzpatrick F, Kuijper EJ; Guideline Committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021;27 Suppl 2:S1-S21. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 103] [Cited by in F6Publishing: 281] [Article Influence: 93.7] [Reference Citation Analysis (0)] |
6. | Rao K, Malani PN. Diagnosis and Treatment of Clostridioides (Clostridium) difficile Infection in Adults in 2020. JAMA. 2020;323:1403-1404. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis (0)] |
7. | McGill SK. Fecal Microbiota Transplant for Severe Clostridioides Difficile Infection: Let's Halt the Raging Fire. Clin Infect Dis. 2021;73:720-721. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis (0)] |
8. | Cammarota G, Ianiro G, Magalini S, Gasbarrini A, Gui D. Decrease in Surgery for Clostridium difficile Infection After Starting a Program to Transplant Fecal Microbiota. Ann Intern Med. 2015;163:487-488. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 43] [Cited by in F6Publishing: 51] [Article Influence: 5.7] [Reference Citation Analysis (0)] |
9. | Hocquart M, Lagier JC, Cassir N, Saidani N, Eldin C, Kerbaj J, Delord M, Valles C, Brouqui P, Raoult D, Million M. Early Fecal Microbiota Transplantation Improves Survival in Severe Clostridium difficile Infections. Clin Infect Dis. 2018;66:645-650. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 79] [Cited by in F6Publishing: 79] [Article Influence: 11.3] [Reference Citation Analysis (0)] |
10. | Popa D, Neamtu B, Mihalache M, Boicean A, Banciu A, Banciu DD, Moga DFC, Birlutiu V. Fecal Microbiota Transplant in Severe and Non-Severe Clostridioides difficile Infection. Is There a Role of FMT in Primary Severe CDI? J Clin Med. 2021;10. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 12] [Reference Citation Analysis (0)] |
11. | Tixier EN, Verheyen E, Luo Y, Grinspan LT, Du CH, Ungaro RC, Walsh S, Grinspan AM. Systematic Review with Meta-Analysis: Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile. Dig Dis Sci. 2022;67:978-988. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 7] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis (0)] |
12. | Brandt LJ, Borody TJ, Campbell J. Endoscopic fecal microbiota transplantation: "first-line" treatment for severe clostridium difficile infection? J Clin Gastroenterol. 2011;45:655-657. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 4.3] [Reference Citation Analysis (0)] |
13. | Beran A, Sharma S, Ghazaleh S, Lee-Smith W, Aziz M, Kamal F, Acharya A, Adler DG. Predictors of Fecal Microbiota Transplant Failure in Clostridioides difficile Infection: An Updated Meta-analysis. J Clin Gastroenterol. 2022;. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
14. | Eze P, Balsells E, Kyaw MH, Nair H. Risk factors for Clostridium difficile infections - an overview of the evidence base and challenges in data synthesis. J Glob Health. 2017;7:010417. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 72] [Cited by in F6Publishing: 111] [Article Influence: 18.5] [Reference Citation Analysis (0)] |
15. | Tschudin-Sutter S, Kuijper EJ, Durovic A, Vehreschild MJGT, Barbut F, Eckert C, Fitzpatrick F, Hell M, Norèn T, O'Driscoll J, Coia J, Gastmeier P, von Müller L, Wilcox MH, Widmer AF; Committee. Guidance document for prevention of Clostridium difficile infection in acute healthcare settings. Clin Microbiol Infect. 2018;24:1051-1054. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 52] [Cited by in F6Publishing: 65] [Article Influence: 10.8] [Reference Citation Analysis (0)] |
16. | Liu D, Zeng L, Yan Z, Jia J, Gao J, Wei Y. The mechanisms and safety of probiotics against toxigenic clostridium difficile. Expert Rev Anti Infect Ther. 2020;18:967-975. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
17. | Saha S, Mara K, Pardi DS, Khanna S. Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Gastroenterology. 2021;160:1961-1969.e3. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 38] [Cited by in F6Publishing: 51] [Article Influence: 17.0] [Reference Citation Analysis (0)] |
18. | Aroniadis OC, Brandt LJ, Greenberg A, Borody T, Kelly CR, Mellow M, Surawicz C, Cagle L, Neshatian L, Stollman N, Giovanelli A, Ray A, Smith R. Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection: A Multicenter Experience. J Clin Gastroenterol. 2016;50:398-402. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 9.3] [Reference Citation Analysis (0)] |